Translational Stroke Research: Vision and Opportunities.
Translational Stroke Research: Vision and Opportunities.
复制标题
DOI:
10.1161/strokeaha.117.017112
复制
发表时间:
2017-09
期刊:
影响因子:
8.3
通讯作者:
Koroshetz W
中科院分区:
文献类型:
--
作者:
Bosetti F;Koenig JI;Ayata C;Back SA;Becker K;Broderick JP;Carmichael ST;Cho S;Cipolla MJ;Corbett D;Corriveau RA;Cramer SC;Ferguson AR;Finklestein SP;Ford BD;Furie KL;Hemmen TM;Iadecola C;Jakeman LB;Janis S;Jauch EC;Johnston KC;Kochanek PM;Kohn H;Lo EH;Lyden PD;Mallard C;McCullough LD;McGavern LM;Meschia JF;Moy CS;Perez-Pinzon MA;Ramadan I;Savitz SI;Schwamm LH;Steinberg GK;Stenzel-Poore MP;Tymianski M;Warach S;Wechsler LR;Zhang JH;Koroshetz W
Bosetti et al NINDS Workshop Recommendations 2633 academia, industry, the Food and Drug Administration, and other public and private funding agencies. In the context of this workshop, translation refers to the research necessary to move a promising therapeutic along the drug development pipeline. Preclinical translational studies need to be designed differently depending on whether they are exploratory or confirmatory. Exploratory approaches may focus on disease mechanisms and use simpler rodent models to gain rigorous information on a putative therapeutic target. However, later-stage confirmatory studies of putative therapies would benefit from the same design features adopted in clinical trials, including heterogeneous populations, adequate sample size, end points predictive of clinical outcomes, and routes of administration similar to therapeutic use, as well as reporting of study results, including negative findings. This special report outlines the discussions and recommendations developed by the workshop participants to help advance translational stroke research, which are summarized in the Table.